All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Novel bispecific antibodies in MM: characteristics and latest data

May 14, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory multiple myeloma.

Bookmark this article

Bispecific antibodies (bsAbs) are a form of T-cell engaging immunotherapy that targets specific surface antigens on myeloma cells as well as the patient’s own T cells, causing direct T-cell activation and tumor cell death. The efficacy rates associated with these agents are markedly high; however, they are also associated with significant adverse events and toxicity.1

Here, we summarize a presentation by Einsele1 delivered at the International Myeloma Society (IMS) 5th Immune Effector Cell Workshop 2024 on novel bsAbs in multiple myeloma (MM) and how the unique characteristics (Figure 1) of these drugs may help overcome the challenges associated with bsAb treatment.

Figure 1. Structures of linvoseltamab, ABBV-383, alnuctamab, and cevostamab* 

BCMA, B-cell maturation antigen; FcRH5, Fc receptor-homolog 5.
*Adapted from Einsele.1 Created with


  • Linvoseltamab is an investigational bsAb that targets B-cell maturation antigen (BCMA) and CD3 on the patient’s T cells.
  • This drug also possesses an anti-albumin domain on the fragment crystallizable (Fc) region, which allows for a reduced dosing frequency.
    • Dosing was reduced to once every 4 weeks (Q4W) as part of the phase I/II LINKER-MM1 (NCT03761108) clinical trial.
  • Topline data from the Q4W dosing schedule in LINKER-MM1 include:
    • An overall response rate (ORR) of 69.2%.
    • Median progression-free survival (PFS) not reached.
    • Any-grade infection rate of 69.2% and 36.2% at Grade 3/4.


  • ABBV-383 is a BCMA-directed bsAb, uniquely possessing two BCMA binding domains and a silenced-FC backbone, designed to extend the half-life of the drug for reduced dosing.
  • Dosing frequencies of once every 3 weeks (Q3W) or Q4W were investigated for their impact on CRS rates, with a 60 mg Q4W schedule resulting in the lowest overall CRS rate at 43%.
    • No incidence of Grade 3 CRS was reported in this cohort.
  • The lowest rates of Grade 3/4 infections were recorded in the Q4W cohort, at 10% compared with 34% in the 60 mg Q3W cohort.
  • Q4W saw the highest ORR at 65% vs 60% in Q3W, as well as a median PFS not reached vs 13.7 months, respectively.


  • Alnuctamab possesses bivalent binding to BCMA with a low CD3-binding domain and modified Fc region, mediating both reduced dosing and lower rates of cytokine release.
  • A Q4W dosing schedule at the 30 mg target dose yielded:
    • An ORR of 67%.
    • A median PFS of 11.4 months, compared with 10.1 months in all target doses.
    • A 12-month PFS rate of 45%, vs 44% in all target doses.


  • Cevostamab targets Fc receptor-homolog 5 (FcRH5), which is expressed on myeloma cells with near 100% prevalence. FcRH5 is also highly expressed at all stages of B-cell maturation and is located near the chromosomal breakpoint.
  • Clinically, cevostamab was evaluated in the heavily pre-treated population, with a median of six prior lines of therapy.
    • The ORR in the 132–198 mg dose level was 56.7% vs 36.1% in the 20–90 mg dose level.
    • None of the patients who experienced a stringent complete response had relapsed by data cut-off.

Key learnings

  • Novel bsAbs in MM are increasingly being developed with low-affinity binding to CD3 as well as a high affinity for the target antigen, resulting in potentially lower rates of CRS.
  • The addition of anti-albumin domains to the FC-binding region also aids in reducing CRS and infusion toxicities.
  • These novel bsAbs facilitate reduced dosing schedules which benefit the patient in the form of longer treatment-free intervals, reduced toxicity, and fewer infections.
  • Reduced dosing schedules can also lead to decreased T-cell exhaustion and, consequently, higher efficacy rates and prolonged PFS.

  1. Einsele H. The next bispecifics: linvoseltamab, alnuctamab, ABBV-383, cevostamab. International Myeloma Society 5th Immune Effector Cell Workshop 2024; Apr 17, 2024; Glasgow, UK.


Subscribe to get the best content related to multiple myeloma delivered to your inbox